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A B S T R A C T
Nail diseases are common, cause signiﬁcant distress and treatments are far from successful. Our aim was
to investigate the potential of UV-curable gels – currently used as cosmetics – as topical drug carriers for
their treatment. These formulations have a long residence on the nail, which is expected to increase
patient compliance and the success of topical therapy. The gels are composed of the diurethane
dimethacrylate, ethyl methacrylate, 2-hydroxy-2-methylpropiophenone, an antifungal drug (amorolﬁne
HCl or terbinaﬁne HCl) and an organic liquid (ethanol or NMP) as drug solvent. Following its application
to a substrate and exposure to a UVA lamp for 2 min, the gel polymerises and forms a smooth, glossy and
amorphous ﬁlm, with negligible levels of residual monomers. No drug-polymer interactions were found
and drug loading did not affect the ﬁlm’s properties, such as thickness, crystallinity and transition
temperatures. In contrast, the organic solvent did inﬂuence the ﬁlm’s properties; NMP-containing ﬁlms
had lower glass transition temperatures, adhesion and water resistance than ethanol-based ones.
Water-resistance being a desired property, ethanol-based formulations were investigated further for
stability, drug release and ungual permeation. The ﬁlms were stable under accelerated stability testing
conditions. Compared to terbinaﬁne, amorolﬁne was released to a greater extent, had a higher ungual
ﬂux, but a lower concentration in the nailplate. However, both drugs were present at considerably high
levels in the nail when their MICs are taken into account. We thus conclude that UV-curable gels are
promising candidates as topical nail medicines.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The nail unit can be subject to numerous disorders, some of
which, for example, onychomycosis (fungal nail infection) and
psoriasis, can be extremely painful, recalcitrant to treatment
(Arrese and Piérard, 2003), and result in psychosocial and
occupational consequences, reducing a person’s quality of life
(Daniel, 2013; Scher, 1996). Onychomycosis affects approximately
14–18% of the general population (Baran et al., 2006; Murdan,
2002, 2008; Murdan, 2013), up to 25% of the geriatric and diabetic
populations (Gupta et al., 1997, 1998; Piérard and Piérard-
franchimont, 2005), and its occurrence is increasing. Current
treatments include topical and oral antifungals. Oral therapy
carries the inherent disadvantages of systemic adverse effects,
drug interactions and contraindications, and is subject to a failure
rate of 20%, as well as a relapse rate of 25% (Gupta, 2012; Roberts,
1999). Topical therapy, on the other hand, has a low success rate* Corresponding author. Fax: +44 207 753 5942.
E-mail address: s.murdan@ucl.ac.uk (S. Murdan).
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0378-5173/ã 2015 The Authors. Published by Elsevier B.V. This is an open access article unwith currently available medicines, for example, 13–54% complete
cure rates from amorolﬁne nail lacquer (Lauharanta, 1992; Paul
et al., 2013; Reinel and Clarke, 1992), similarly low cure rates from
ciclopirox nail lacquer (Gupta and Joseph, 2000), under 20%
complete cure rate of eﬁnaconazole solution (Tosti, 2013) and
under 30% cure rate of tavaborole solution (Markham, 2014). Nail
psoriasis affects approximately 1% of the population (Reich, 2009)
and its treatment may involve repeated injections of corticoste-
roids into the nail folds, injections of biological agents such as
adalimumab, photochemotherapy, topical or systemic treatment
depending on the symptoms (Oram and Akkaya, 2013). The
adverse effects of injections, photochemotherapy and systemic
therapy, such as pain, radiation overexposure, systemic toxicity
and drug interactions, make topical therapy very attractive;
however topical management remains a challenge due to the
low drug penetration through the nail plate.
Attempts to improve the efﬁcacy of topical nail medicines are
ongoing with the development of new drugs with optimised
physiochemical properties and new drug carriers. Some of these
are described in (Elsayed, 2015; Naumann et al., 2014). A number of
the new formulations are water-soluble and need to be applied everyder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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therapeutic success. Given that patients’ adherence to treatment, in
general (Sabaté, 2003), and to topical nail therapy (Zhou et al., 2011)
is low, we are investigating longer-lasting UV-curable gel formula-
tions which could act as a drug-depot on the nail plate.
UV-curable gel formulations are currently used as nail
cosmetics, where they are commonly known as UV gels (Barel
et al., 2009; Draelos, 2010; Schoon, 2005). The formulations
typically contain three components: a urethane methacrylate
based monomer (at 75–85% w/w), (meth) acrylate based mono-
mers (at 15–25% w/w) and a polymerisation photoinitiator (at
1–3% w/w). Following application of the formulation on the nail
plate surface, the nail is placed under a UVA lamp for
approximately 2 min. The UVA light initiates polymerisation and
a glossy, cosmetically-acceptable polymeric ﬁlm is formed on the
nail plate. The ﬁlm has a long residence on the nail plate and we
propose that such a ﬁlm could be used as a drug carrier to improve
the topical therapy of nail diseases. The formulation would be
applied and removed (when desired) by a healthcare professional
(e.g. podiatrist) treating the patient.
The aim of the work presented in this paper was to investigate
the pharmaceutical potential of such formulations. The objectives
were to formulate and characterise such UV-curable gels, in terms
of the formulation components, polymerisation, and the resulting
ﬁlm’s properties, such as morphology, microstructure, thermal and
viscoelastic properties, adhesivity, water sensitivity, stability and
the loading, release and ungual (i.e. of the nail) permeation of
loaded drug. Anti-fungal drugs were used as onychomycosis is the
most common nail disease, although these formulations are
expected to be suitable for other nail diseases.
UV gelshave beenwidely usedas cosmetics since1982. Thus, they
have a fairly long safety record, although a few cases of
hypersensitivity and allergic reactions have been reported (Cravo
et al., 2008; Erdmann et al., 2001; Fisher, 1990; Hemmer et al.,1996;
Kanerva et al., 1996; Vázquez-Osorio et al., 2014). Such adverse
reactions are caused by the monomers (rather than the polymer) and
occur after several months of overexposure. The cured ﬁlm does not
pose a hazard (Draelos, 2010), and the adverse reactions can be
avoided by applying the formulation to the nail plate only and
avoiding the skin surrounding the nail plate. This is done by leaving a
formulation-free margin at the nail folds (Draelos, 2010; Schoon,
2005). The use of UVA radiation to trigger polymerisation is not
consideredariskfactor. Recentresearchsuggestedthat twohands(of
a person) placed in a UV nail lamp for 10 min twice a month (as could
happen for cosmetic use) is equivalent to that person spending an
extra 2.7 min insunlighteveryday foramonth(Schoonetal.,2010). It
hasalso been reportedthat a person could use a UVnail lampfor2.8 h
every day without any requirement for warning or protective
measures (Dowdy and Sayre, 2013), and that the UVA radiation
emitted by UVA nail lamps speciﬁcally designed for curing UV gels
pose a low risk of skin cancer even when used weekly for over
250 years (Alina and Martin, 2013).
2. Materials and methods
2.1. Materials
Amorolﬁne HCl was purchased from Ranbaxy Research Labora-
tories (Haryana, India) and terbinaﬁne HCl from AK Scientiﬁc (CA,
USA). Diurethane dimethacrylate, ethyl methacrylate, 2-hydroxy-2-
methylpropiophenone, absolute ethanol, methanol, 1-methyl-2-
pyrrolidinone (NMP), propan-2-ol, triethylamine, phosphoric acid
85% wt. solution in water, triﬂuoroacetic acid and a dialysis
tubing cellulose membrane (MW 10281) were purchased from
Sigma–Aldrich (Dorset, UK). Acetonitrile HPLC gradient grade was
purchased from Fisher Scientiﬁc (Hertfordshire, UK).2.2. Methods
2.2.1. Determination of drug (amorolﬁne HCl and terbinaﬁne HCl)
solubility in monomers and in solvents (ethanol and NMP)
Saturation solubility studies were carried out to determine the
solubilities of the antifungal drugs in the monomers and solvents
used. The antifungals were added in excess to vials containing 2 ml of
the monomers or solvents. The mixtures were left to stir on a
magneticstirrerplacedinawaterbathat25 C for 72 h.Subsequently,
1 ml of each sample was withdrawn from the vial using a syringe and
passed through a 0.22mm MILLEX1 GP ﬁlter unit into an Eppendorf
tube. The samples were then centrifuged using a bench centrifuge for
20 min at a speed of 13.2  1000 rpm. The supernatant for each
sample was then collected and diluted by 50,100 or 1000 times with
ethanol (or NMP – for the solubility determination in NMP) and
analysed by HPLC (described in Section 2.4.1).
2.2.2. Formulation preparation
A total of three types of formulations were prepared:
1. Drug-free, solvent-free formulations were prepared by mixing
the two monomers (145.5 ml of ethyl methacrylate and
diurethane dimethacrylate to one millilitre) with the photo-
initiator (30 ml), and leaving the mixture to stir overnight, to
produce a clear homogenous solution.
2. Drug-free, solvent-containing formulations were prepared by
dissolving the monomers in a solvent (ethanol or NMP). To
determine the optimal concentration of solvent, ethanol-
containing formulations at concentrations of 25, 30, 35, 40,
45 and 50% v/v were prepared. Films were formed as described
below and tested as described in Section 2.3. The optimal
solvent concentration was found to be 25% v/v.
3. Formulations containing drug (at 1–5% w/v) and solvent
(ethanol or NMP at 25% v/v) were prepared by ﬁrst dissolving
the drug in the chosen solvent and then adding the two
monomers and photoinitiator to this drug solution. This mixture
was left to stir overnight to produce a clear homogenous
solution.
2.2.2.1. UV-curing of formulations. The formulation (30 ml) was
applied using a pipette tip on a microscope glass slide (to an area of
15 mm  15 mm) as a single layer. The glass slide was placed under
a 36 Watt Cuccio Professional UVA nail lamp (purchased from
Amazon, UK) for 2 min. This caused curing of the formulation and
formation of a ﬁlm. The surface of the ﬁlm was wiped with propan-
2-ol using a super absorbent 4 ply lint-free nail wipe to remove the
oxygen inhibition layer, (an unreacted monomer layer). This
revealed a glossy polymer ﬁlm, which was then removed from the
glass slide using a scalpel and used in characterisation studies
described below.
2.2.3. Assessment of the polymerisation process and formation of the
UV-cured ﬁlm
2.2.3.1. Percentage mass conversion from monomer to cured polymer
ﬁlm. The percentage mass conversion from monomer mixture to
polymer ﬁlm was calculated using the following equation:
Mass conversionð%Þ ¼ Wt
Wo
 
 100
where W0 is the weight of the monomer mixture before curing and
Wt is the weight of the UV-cured ﬁlm.
2.2.3.2. Fourier transform infrared (FT-IR) spectroscopy. Infrared
spectroscopy was used to assess the polymer structure and the
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the degree of conversion (DC) from monomer mixture to polymer
ﬁlm. Spectra of the uncured and cured formulations were obtained
using the OPUS 7.0 software and recorded by a Bruker Alpha IR
Spectrophotometer (Bruker Corporation, Germany), using 24 scans
over the 400–4000 cm1 range with background subtraction. The
DC% was calculated from the ratio of the height of the absorbance
peak of the aliphatic C¼C bond (1636 cm1) relative to that of the
carbonyl group (>C¼O, 1702 cm1), used as an internal standard,
using the following equation:
DCð%Þ ¼ ðA1636=A1702Þ0  ðA1636=A1702ÞtðA1636=A1702Þ0
 100
where (A1636/A1702)0 and (A1636/A1702)t are relative absorbance of
C¼C bonds to C¼O before curing and after curing respectively.
2.3. Characterisation of UV-cured polymer ﬁlm
Visually, the cured ﬁlms were smooth, transparent and glossy.
The ﬁlms were characterised for thickness, microstructure, residual
monomers, maximum drug-load, thermal properties, stability, drug
release and ungual drug permeation. Stability, drug release and
ungual drug permeation were only tested for ethanol-based
formulations as the NMP-based ones were not resistant to water.
The thickness of the ﬁlms produced was measured using a
Sealey AK9635D 0–25 mm Digital External Micrometer (PVR
Direct, UK). Each ﬁlm was measured at three separate points
and an average was taken. Precautions were taken to measure the
thickness without compressing the polymer ﬁlm.
Scanning electron microscopy (SEM) was used for imaging the
surface of the polymer ﬁlms produced. The samples were gold
sputter coated (10 nm) and imaged using FEI Quanta 200F
(Eindhoven, The Netherlands).
Maximum drug-load determinations were conducted using
polarised light microscopy (PLM) and X-ray diffraction (XRD). To
determine the maximum (soluble) drug-load in the ﬁlms, the latter
were examined by PLM for the absence/presence of drug crystals
using a Nikon Microphot-FXA microscope (Nikon Corporation,
Tokyo, Japan) and polarising ﬁlters. Images were taken using a
Lumenera Inﬁnity 2 digital camera (Lumenera Corporation,
Ottawa, Canada) attached to the microscope. XRD was used: (i)
to determine the crystallinity/amorphousness of the UV-cured
ﬁlms and (ii) to conﬁrm the maximum (soluble) drug-load of the
ﬁlms determined by PLM. X-ray diffraction spectra of the
antifungals and of the polymer ﬁlms were obtained using a Rigaku
MiniFlex 600 X-ray diffractometer (Rigaku Corporation, Tokyo,
Japan) equipped with MiniFlex Guidance software. The samples
were scanned over an angular range of 2–60, with a step size of
0.02 and step duration of 0.5/min. The generator voltage was set
at 40 kV and the current at 15 mA. The data was analysed using
OriginPro 9.0.
The exact drug-load in UV-cured polymer ﬁlms was deter-
mined by ultrasonic extraction using a Transonic T460/H sonicator
(Elma, Germany). Ten milligrams of each ﬁlm was placed in a glass
vial. Five millilitres of ethanol was added to the ﬁlm and the vial
was sonicated for up to 2 h. Subsequently the solvent was analysed
by HPLC (as per Section 2.4.1). This method was optimised for the
stated solvent volume and extraction time.
The levels of residual monomers in the polymer ﬁlm were
quantiﬁed by ultrasonic extraction. Immediately after curing, one
gram of each ﬁlm was placed in a glass vial and three millilitres of
methanol was added. The mixture was sonicated for up to 2 h.
Subsequently the solvent was analysed using GC (as per Section
2.4.1 to quantify the extracted residual monomers. The optimal
duration and volume of extraction solvent were determined after a
series of experiments.Thermal gravimetric analysis (TGA) was used to determine the
thermal stability of the polymer ﬁlms. It was conducted using the
Discovery TGA Model (TA Instruments–Waters LLC, Delaware,
USA). Oxygen-free nitrogen gas with a ﬂow rate of 25 ml/min was
used. The sample mass was approximately 4 mg, and each sample
was heated from 25 to 500 C, with a heating rate of 10 C/min. Data
analysis was carried out with TA Instruments TRIOS V3.1.0.3538.
Differential scanning calorimeter (DSC). The thermal proper-
ties of the polymer ﬁlms were also analysed by, using the Q2000 TA
Instruments (Waters LLC, Delaware, USA), equipped with TA
Universal Analysis 2000 software. Oxygen-free nitrogen gas with a
purge rate of 50 ml/min was used. Approximately 8 mg of sample
was contained within a T-zero pan following seal with a T-zero
hermetic lid. Each sample was heated from 30 C to 250 C with a
heating rate of 10 C/min.
Dynamic mechanical analysis (DMA) was used to study the
viscoelastic behaviour of the polymer ﬁlms as a function of
temperature. Films with an area of 15 mm  6.5 mm (produced
after curing 13 ml of the formulation) were prepared and analysed
using the Q800 Dynamic Mechanical Analyser (TA Instruments–
Waters LLC, Delaware, USA). The mode was set at DMA multi-
frequency-strain using a ﬁlm tension clamp. The purge gas used
was nitrogen, and the heating range was from room temperature to
200 C with a heating rate of 3 C/min. The oscillating frequency
was set at 1 Hz. A preload force (0.01 N) was applied to the sample
prior to the dynamic oscillating force to prevent the ﬁlm buckling
and the force track was maintained at 125%. The data was collected
using Advantage for Q Series Version 2.8.0.394, and the data
analysis was carried out with TA Instruments Universal Analysis
2000. The glass transition temperature (Tg) was calculated as the
tan d peak.
UV-cured polymer ﬁlm’s adhesivity. The cross-cut test
(adapted from ISO 2409:2013 – paints and varnished – cross-cut
test) was used to assess the resistance of the polymer ﬁlms to
separation from a substrate (i.e. the ﬁlms adhesion to the
substrate) when a right-angle lattice pattern is cut into the ﬁlm,
penetrating through the substrate. A single layer of the UV-curable
gel formulation (1.68 ml) was cured to a 70  180 mm area on the
smooth surface of a high density polyethylene (HDPE) sheet (RS
Components, UK) and was left to age for 24 h. Prior to testing, the
thickness of the ﬁlm was measured using a micrometre. A cross-
hatch pattern was then cut manually into the polymer ﬁlm using a
scalpel (blade thickness of 0.38 mm, Swann–Morton, Shefﬁeld, UK)
by applying uniform pressure at a uniform cutting rate. A total of
six parallel cuts were made in the direction of gel application,
followed by six perpendicular cuts to form a lattice. The cuts made
were 3 mm apart as the ﬁlm thickness was between 121 and
250 mm. The loose ﬁlm was then removed by brushing the
substrate lightly with a soft brush several times backwards and
forwards and several times forwards along each of the diagonals of
the lattice pattern. This cross-hatch pattern was examined visually
to assess the extent to which the polymer ﬁlm had been removed
off the polyethylene sheet. The ﬁlm’s removal was scored as
follows: 0 = lattice is totally unaffected; 1 = some small ﬂakes of
ﬁlm are detached at the intersections of the cuts with less than 5%
of the lattice area being affected; 2 = the ﬁlm has ﬂaked along the
edges and/or at the intersections of the cuts with a cross cut area
greater than 5% but less than 15% being affected; 3 = the ﬁlm has
ﬂaked along the edges of the cuts partly or wholly in large ribbons,
and/or on different parts of the squares, with a cross-cut area 15%
but 35% being affected; 4 = the ﬁlm has ﬂaked along the edges of
the cuts in large ribbons or some squares have detached partly or
wholly with a cross-cut area >35% but <65% being affected; 5 = any
degree of ﬂaking or detachment that cannot be classiﬁed under 4. A
high score therefore reﬂected poorer resistance of the ﬁlm to
removal from the substrate (i.e. poor adhesion).
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from ASTM D870 – standard practice for testing water resistance of
coatings using Water Immersion) was used to determine the
resistance of the cured ﬁlms to water. The formulation (140 ml) was
cured to a 15 mm by 70 mm area onto the smooth side of a HDPE
sheet. The latter was then placed in a distilled water bath (Grants
Instruments Ltd., Cambridge, England) at room temperature
(25 C) such that half the length of the ﬁlm strip was immersed
in water, while the other half was outside. At timed intervals,
(initially every 10 min for 1 h, then hourly for 8 h and ﬁnally every
24 h for two days), the HDPE sheets were taken out of the water
bath to observe the effect of water immersion on the polymer ﬁlm.
The ﬁlm’s sensitivity/resistance to water was scored as 0 for no
change in ﬁlm, 1 for 25% blister formation, 2 for >2550% blister
formation, 3 for >5075% blister formation and 4 for complete ﬁlm
removal. Therefore a high score indicated high sensitivity to water.
The extent of blister formation was reported since other factors
such as colour, were not affected.
The stability of ethanol-based drug-loaded gel formulations, as
well as that of the UV-cured ﬁlms was tested over 3 months under
accelerated testing conditions, i.e., 40  2 C and 75% RH  5% RH.
This was conducted by placing the formulations and ﬁlms in a
desiccator containing a saturated solution of sodium chloride and
placing this in a 40 C oven. At timed intervals, the formulations
were assessed for (i) visual appearance, (ii) drug concentration and
(iii) the quality of the ﬁlm produced (in terms of the presence of
drug crystals and drug concentration) over time. The incubated
polymer ﬁlms were observed for (i) drug crystallisation and (ii) the
drug concentration. Polarised light microscopy was used to
visualise the presence of crystals in the ﬁlm, if any. HPLC (as per
Section 2.4.1) was used to determine whether the drug content in
the gels and ﬁlms was stable with time.
Drug release from ﬁlms was measured in order to determine
the proﬁle of drug release from the UV-cured ﬁlm, and whether
this inﬂuences ungual drug permeation. The formulations tested
were the 3% w/v amorolﬁne HCl UV-curable gel formulation, a
commercially available amorolﬁne HCl 5% w/v nail lacquer
(Curanail) for comparative purposes, and the 4% w/v terbinaﬁne
HCl UV-curable gel formulation. The study was carried out using
Franz diffusion cells, and the drug-loaded ﬁlms were supported on
a cellulose membrane. The receptor ﬂuid was a 0.1 M phosphate
buffer at pH 5 as both amorolﬁne HCl and terbinaﬁne HCl are stable
at this pH (Hossin, 2014). Sink conditions were maintained
throughout the duration of the study.
To set up the Franz cell, a dialysis tubing cellulose membrane
was cut into a circle with an area of 4.909 cm2. A test formulation
was then applied onto the surface of the cellulose membrane,
covering a circular area of 0.9503 cm2. This was allowed to dry, in
the case of Curanail. For the UV-curable gel formulations, the
cellulose membrane was placed under a UVA lamp and the
formulation was cured for 2 min. The surface of the ﬁlm produced
was then wiped with propan-2-ol using a nail wipe. The cellulose
support with the UV-cured or air-dried Curanail ﬁlm was then
placed between the donor and receptor compartments of a Franz
diffusion cell, with the test ﬁlms facing the donor side, and the
compartments were clamped together. Subsequently, four ml ofTable 1
HPLC method for the quantiﬁcation of amorolﬁne HCl and terbinaﬁne HCl in samples.
Drug Mobile Phase 
Amorolﬁne
HCl
0.1% triﬂuoroacetic acid:acetonitrile (55:45 v/v) 
Terbinaﬁne
HCl
0.012 M triethylamine + 0.020 M phosphoric acid:acetonitrile (65:35
v/v)receptor ﬂuid was added to the receptor compartment while
ensuring that no air bubbles were introduced. The diffusion cells
were left to stir on a magnetic stirrer placed in a water bath
maintained at 32 C. Samples of the receptor ﬂuid were collected at
pre-determined time intervals for 30 days. Half ml was collected
via the receptor arm and replaced with 0.5 ml of fresh buffer at
each sampling point. The samples were analysed by HPLC (as per
Section 2.4.1) to determine the amount of drug released, and the
cumulative% drug release over time was plotted. The UV-cured and
Curanail ﬁlms were also observed by polarised microscopy prior to
the release study and at day 30 to determine if there was any drug
crystallisation and precipitation out of the ﬁlm during the release
study.
In vitro drug permeation study was carried out in order to
determine whether the polymer ﬁlms produced show potential as
topical ungual drug carriers. The formulations tested were the 3%
w/v amorolﬁne HCl UV-curable gel formulation, the amorolﬁne
HCl 5% w/v nail lacquer (Curanail) and the 4% w/v terbinaﬁne HCl
UV-curable gel formulation. The study was carried out using a
modiﬁed Franz diffusion cell. Human nail clippings (ﬁngernails)
were obtained from healthy volunteers aged between 18 and
65 years, washed with water and soaked in distilled water for one
hour prior to use. They were then cut to size (circular, with a
diameter of 0.3 cm) and measured for thickness using a micro-
metre. A layer of the formulation (using 2 ml) was applied on the
nail surface with a pipette tip and allowed to dry in the case of
Curanail. For the UV-curable gel formulations, the formulation
(2 ml) was applied on the nail surface and cured under an UVA lamp
for 2 min. The surface of the ﬁlm produced was then wiped with
propan-2-ol using a nail wipe. The nail was placed in the donor
compartment and ﬁxed into place, such that when assembled with
the receptor compartment, the under-surface of the nail alone was
exposed to the receptor ﬂuid. The area exposed was 0.025 cm2.
Subsequently, 900 ml of receptor ﬂuid was added to the receptor
compartment. The receptor ﬂuid was 0.1 M phosphate buffer pH 5.
The diffusion cell was assembled, covered with paraﬁlm, and left to
stir on a magnetic stirrer placed in a water bath at 32 C. Samples of
the receptor ﬂuid were collected over 30 days by taking 50 ml of
receptor ﬂuid for analysis via the receptor arm and replacing it
with 50 ml of fresh buffer. The samples were analysed by HPLC (as
per Section 2.4.1) to determine the amount of drug permeated
across the nail over time. Each experiment was repeated six times.
At the end of the permeation study, the nail clipping was
removed from the donor compartment using forceps. The ﬁlm on
the nail surface was carefully lifted off the nail using a scalpel and
placed in a vial containing 1 ml of ethanol. The mixture was
ultrasonicated for 2 h and the solvent was analysed by HPLC to
quantify the amount of drug remaining in the donor compartment.
The nail plate was rinsed with distilled water and blotted dry with
Kimwipes, before placing in a vial containing 1 ml of ethanol. This
was ultrasonicated for 2 h and the solvent was analysed with HPLC
while the nail clipping retrieved was placed in another vial
containing 1 ml of ethanol for a further two hour sonication. This
extraction procedure was repeated until no further drug was
extracted. The total amount of drug extracted from the nail was
then calculated.Flow rate (ml/
min)
Sample injection vol.
(ml)
Wavelength
(nm)
Retention time (min)
1.0 20.0 220 5.8
1.0 20.0 224 8.8
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Fig. 1. Water sensitivity (at 48 h incubation) of ﬁlms produced by UV-curable gel
formulations containing between 0 and 50% v/v ethanol. Mean  standard deviation
are shown, n = 3. Where no error bars are shown, the standard deviation was zero.
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2.4.1. High-performance liquid chromatography (HPLC)
The amount of amorolﬁne HCl and terbinaﬁne HCl in samples
was quantiﬁed by using a 1260 Inﬁnity Agilent HPLC system
equipped with an autosampler and a variable wavelength
absorbance detector (Agilent Technologies, Germany). Elution
was performed using a Luna C18 column (150  4.6 mm, 5 mm) at a
temperature of 40 C. Table 1 shows the HPLC method developed,
which was validated for linearity, precision and accuracy (Hossin,
2014).
2.4.2. Gas chromatography (GC)
GC was conducted to determine the amount of diurethane
dimethacrylate and ethyl methacrylate in samples using a 7890A
GC System (Agilent, USA) equipped with a ﬂame ionisation
detector (FID) system. Chromatographic separation was achieved
on a HP-5 column (30 m long  320 mm inside diameter with
0.25 mm ﬁlm thickness). The sample injection volume was 2 ml.
The injector was in the split mode (100:1) and its temperature was
maintained at 250 C throughout the experiments. The column
temperature was raised from 45 C (hold 2 min) to 110 C
(hold 2 min) at a 10 C/min heating rate to 280 C (hold 2 min)
at a 20 C/min heating rate. The ﬂow rate of carrier gas (N2) was
1.5 ml/min. The detection was carried out by the FID with the
temperature of 280 C and the ratio of H2/air at 25/250. Diurethane
dimethacrylate and ethyl methacrylate were detected at 16.5 and
6.5 min respectively. The method developed was validated for
linearity, precision and accuracy.
2.5. Statistical analyses
All the experiments described above were repeated three times
(except for the in vitro drug permeation study which was repeated
six times). Statistical calculations were conducted using SPSS 22.
The two-sample t-test was carried out for testing signiﬁcant
differences in two data sets and the one-way analysis of variance
(ANOVA) and post hoc Tukey were carried out for all statistical
analyses involving more than two data sets. Repeated measures
ANOVA and post hoc Tukey test were carried out to identify any
statistically signiﬁcant differences in release and permeation
proﬁles of the antifungals from the polymer ﬁlms over time.
3. Results and discussion
3.1. Components of the UV-curable gel formulations
A number of monomers and photoinitiators that are used in the
cosmetic industry were considered and ﬁnally, diurethane
dimethacrylate, ethyl methacrylate and 2-hydroxy-2-methylpro-
piophenone were chosen. Diurethane dimethacrylate was used as
the backbone of the formulation due to its ability to produce a
strong cross-linked polymer which imparts exceptional abrasion
resistance and adhesion, and also due to its clarity, viscosity and
inherent resistance to discoloration (Murray, 2012). Ethyl methac-
rylate was chosen for its ability to enhance ﬁlm ﬂexibility and as its
safety has been extensively assessed and been found to be
favourable (Panel, 2002). 2-Hydroxy-2-methylpropiophenone was
chosen as the photoinitiator as it is capable of forming hard ﬁlms, is
useful for non-yellowing applications, and has good solvency
properties (Segurola et al., 1999).
The drugs amorolﬁne HCl and terbinaﬁne HCl were selected for
their high potencies against onychomycosis-causing dermato-
phytes. Unfortunately the solubility of these drugs in the gel
components was negligible. Both drugs were insoluble in
diurethane dimethacrylate, while, in ethyl methacrylate,amorolﬁne HCl dissolved at 0.10  0.01 mg/ml and terbinﬁne HCl
dissolved at 0.66  0.19 mg/ml at 25 C. This poor drug solubility
necessitated the inclusion of a solvent in the system to achieve a
reasonable drug load. Two solvents – ethanol and NMP – were
selected for their miscibility with the monomer blend and their
solvency for the drugs. Ethanol dissolves amorolﬁne HCl at
119.5  5.4 mg/ml and terbinaﬁne HCl at 141.30  1.7 mg/ml at
25 C, while NMP dissolves amorolﬁne HCl at 56.2  2.1 mg/ml and
terbinaﬁne HCl at 106.6  1.3 mg/ml at 25 C.
3.2. Proportions of the different gel components
The proportions of diurethane dimethacrylate, ethyl methacry-
late and 2-hydroxy-2-methylpropiophenone were similar to those
in cosmetic UV gels, with the ratio of diurethane dimethacrylate to
ethyl methacrylate kept at 85:15% v/v and the photoinitiator
concentration set at 3% v/v of the mixture of monomers and
photoinitiator.
The amount of drug that could be loaded in the gel depended on
the amount of solvent (ethanol/NMP) that could be incorporated.
Formulations containing ethanol at concentrations 25–50% v/v
produced ﬁlms that were thinner and had a lower percentage mass
conversion from monomer to polymer as the solvent concentration
increased. Ethanol inclusion in the gel also increased the water-
sensitivity of the UV-cured ﬁlms (tested as described in Section
2.3) in a concentration dependent manner (Fig. 1). As the water-
resistance of a nail preparation is critical to its residence on the nail
(Murdan et al., 2015), a solvent concentration of 25% v/v was
chosen as a compromise between the ability of the formulation to
contain sufﬁcient drug and to be water-resistant.
A high drug loading in a nail medicine is desired such that drug
movement out of the preparation and into the nail along the
thermodynamic activity is favoured. It was found that inclusion of
ethanol (at 25% v/v) in a gel formulation allowed the loading of 3%
w/v amorolﬁne HCl or 4% w/v terbinaﬁne HCl. Meanwhile,
inclusion of NMP, also at 25% v/v, allowed the inclusion of 1%
w/v of amorolﬁne HCl or 1% w/v of terbinaﬁne HCl. The lower drug
load enabled by NMP reﬂects its lower solvency for the drugs as
detailed in Section 3.1.
3.3. Preparation of UV-cured ﬁlm
Drug-free gel formulations were prepared by mixing the two
monomers and the photoinitiator, and leaving the mixture to stir
overnight, which produced a clear homogenous solution. Drug-
loaded formulations were prepared by ﬁrst dissolving the drug in
the chosen solvent and then adding the two monomers and
photoinitiator to this drug solution and leaving the mixture to stir
overnight. This also produced a clear homogenous solution.
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Fig. 2. FT-IR spectra of solvent-free and drug-free monomer formulation and the
resulting polymer ﬁlm after UV-curing.
Table 2
Percentage degree of conversion (DC) from monomers to polymer. Means 
standard deviation are shown, n = 3.
Formulation DC (%)
Solvent-free and drug-free gel 51.3  4.5
Drug-free gel containing ethanol 61.3  4.5
Gel containing ethanol and 3% w/v Amorolﬁne HCl 59.5  3.6
Gel containing ethanol and 4% w/v Terbinaﬁne HCl 62.7  3.4
Drug-free gel containing NMP 63.3  4.7
Gel containing NMP and 1% w/v Amorolﬁne HCl 60.2  5.6
Gel containing NMP and 1% w/v Terbinaﬁne HCl 59.7  5.0
Table 4
Thickness of UV-cured polymer ﬁlms. Means  standard deviation are shown, n = 3.
Formulation Film thickness (mm)
Solvent-free and drug-free gel 211.1  6.0
Drug-free gel containing ethanol 161.1  7.8
Gel containing ethanol and 3% w/v Amorolﬁne HCl 163.3  8.7
Gel containing ethanol and 4% w/v Terbinaﬁne HCl 164.4  7.3
Drug-free gel containing NMP 165.6  7.3
Gel containing NMP and 1% w/v Amorolﬁne HCl 167.8  8.3
Gel containing NMP and 1% w/v Terbinaﬁne HCl 166.7  7.1
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a glass slide and exposed to a UVA lamp. Exposure of the gel
formulation to UVA light initiated polymerisation to form a
diurethane dimethacrylate/ethyl methacrylate copolymer, where
the original C¼C alkene bonds in the acrylate moieties of the
monomers were converted to alkane ones (See Supplementary
data for proposed reaction pathway). Polymerisation and the
conversion of C¼C to saturated bonds was conﬁrmed by FT-IR
(Fig. 2), where the C¼C stretching related absorption band at
1636 cm1 were much weaker upon UV-curing.
The existence of a small C¼C peak in the UV-cured ﬁlm (Fig. 2)
indicates that conversion of the monomers to the polymer was not
complete. This is due to the fact that UV-curing was conducted
under ambient conditions. Atmospheric oxygen is known to inhibit
polymerisation; thus as unreacted layer – called the oxygen
inhibition layer (Draelos, 2010; Schoon, 2005) – is formed on the
surface of the polymer ﬁlm. As practised in the cosmetic industry,
this unpolymerised layer was removed by wiping the ﬁlm surface
with a super absorbent 4 ply lint-free nail wipe soaked in propan-
2-ol. Wiping the surface resulted in the removal of 10–15% of the
mass of the ﬁlm ﬁrst formed upon UV exposure.Table 3
Concentration of residual monomers in the UV-cured polymer ﬁlms. Mean levels of m
Formulation Diuretha
Solvent-free and drug-free gel 2.9  0.0
Drug-free gel containing ethanol 0.7  0.0
Gel containing ethanol and 3% w/v Amorolﬁne HCl 0.7  0.0
Gel containing ethanol and 4% w/v Terbinaﬁne HCl 0.7  0.0
Drug-free gel containing NMP 0.4  0.0
Gel containing NMP and 1% w/v Amorolﬁne HCl 0.4  0.0
Gel containing NMP and 1% w/v Terbinaﬁne HCl 0.3  0.03.4. Degree of conversion and amount of residual monomers in cured
polymer ﬁlm
Following the removal of the oxygen inhibition layer, the
polymer ﬁlm was re-examined by FT-IR to measure the extent of
polymerisation within the bulk of the ﬁlm. The% degree of
conversion – using the change in alkene group peak – was found to
be between 50 and 63% (Table 2). Such a degree of conversion
reﬂects values (43–73%) reported for photo-activated dental
composites (Halvorson et al., 2003). The presence of a solvent or
of a drug did not cause any signiﬁcant changes in the percentage
degree of conversion.
To determine whether the less than 100% degree of conversion
shown in Table 2 was due to the presence of unreacted monomers
or the presence of unreacted groups within reacted monomers, the
level of monomers in polymer ﬁlms was quantiﬁed following their
extraction. The amount of diurethane dimethacrylate and ethyl
methacrylate monomers in the polymer ﬁlms were found to be
extremely low, especially in ﬁlms produced from solvent-
containing gels (Table 3). This low level indicates that the 60%
degree of conversion shown in Table 2 is due to the presence of
unreacted groups within the polymer, rather than unreacted
monomers.
It seems that a signiﬁcant proportion of the methacrylate
groups of the diurethane dimethacrylate monomer are not
involved in the polymerisation reaction. This could be due to
restricted mobility of some of the side chains in the viscous
polymerising mixture. The presence of solvent in the formulation
resulted in a small increase, (although this was not statistically
signiﬁcant), in the degree of conversion (Table 2) and a signiﬁcant
decrease (ANOVA, p < 0.05) in the amount of unreacted monomers
(Table 3). It seems that the solvent increased polymerisation,
possibly due to a reduction in the viscosity of the polymerising
mixture (from 0.4 Pas for solvent-free formulations to 0.02 Pas for
ethanol- and NMP-containing formulations) and a subsequent
increase in the mobility of the chains.
The negligible amounts of monomers in drug-containing
UV-cured ﬁlms (Table 3) show that such UV-curable formulations
can be used as topical nail medicines, especially if a formulation-
free margin is left around the nail to avoid contact with the skin, as
the monomers (but not the polymer) have the potential of causing
allergic contact dermatitis (Zondlo Fiume, 2002).onomers in ﬁlm  standard deviation are shown, n = 3.
ne dimethacrylate (% w/w) Ethyl methacrylate (% w/w)
4 0.1  0.002
3 0.003  0.0001
3 0.003  0.00008
3 0.005  0.002
09 0.003  0.0001
1 0.003  0.00008
08 0.002  0.00001
Fig. 3. Scanning electron micrographs of: drug-free and solvent-free ﬁlm (A–C); drug-free ﬁlm with ethanol (D–F); drug-free ﬁlm with NMP (G–I); ﬁlm with ethanol and
amorolﬁne (J–L); ﬁlm with ethanol and terbinaﬁne (M–O). A, D, G, J, M – top surfaces (i.e. exposed to UV light); B, E, H, K, N – under surfaces (i.e. in contact with the support); C,
F, I, L, O – cross-sectional surfaces.
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Fig. 5. Polarised light micrograph and corresponding XRD pattern of amorolﬁne
HCl and ethanol loaded ﬁlm at the concentration at which it is saturated.
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Drug-free, solvent-free UV-cured ﬁlms were transparent,
visually smooth and about 200 mm thick (Table 4). Films produced
when formulations contained a solvent were signiﬁcantly
(p < 0.05) thinner at about 165 mm due to the lower monomer
content in the mixture (Table 4).
Scanning electron microscopy (Fig. 3A–O) of UV-cured ﬁlms
with/without solvent and with/without drug revealed a generally
rough surface of the side that was exposed to UV light and a muchTable 5
Mass yield and drug yield of formulations after UV-curing and removal of oxygen inhi
Solvent in formulation Drug-free formulation Film containing
Mass yield Mass yield 
None 90.7  0.3 NA 
Ethanol 85.1  1.6 85.9  1.9 
NMP 85.8  1.3 85.9  0.5 smoother surface where the ﬁlm had been formed in contact with
the support. The latter provides a certain containment for the
ﬂow of the ﬂuid during polymerisation and the smooth ﬁlm
surface reﬂects the smooth surface of the support. The cross-
sectional views show a fairly dense ﬁlm interior. Inclusion of the
solvent ethanol in the gel formulation seems to have no inﬂuence
on the ﬁlm microstructure, while inclusion of NMP results in ﬁlms
with smoother top and cross-sectional surfaces. NMP seems to
inﬂuence polymerisation to a greater extent than ethanol,
probably due to its higher boiling point of 204 C (vs 78 C for
ethanol). While much of the ethanol originally present in the gel
formulation is expected to evaporate off during UV curing, NMP is
likely to remain in the ﬁlm and inﬂuence the polymer formed. To
investigate this further, UV-cured ﬁlms were stored under
ambient conditions (22  2 C and 50  5% RH) and weighed over
time. While the ﬁlms formed from solvent-free formulations
showed negligible change in mass over 28 days, those formed
with ethanol-containing formulations lost 1 0.4%, 3  1% and
3.5  0.8% of their mass at 24 h, 14 days and 28 days respectively,
and those formed with NMP-containing formulations lost 70.1%,
110.1% and 120.04% of their mass at the same respective times.
The differences in mass loss were statistically signiﬁcant
(p < 0.05). The mass loss is thought to be due to solvent loss
from the ﬁlm and shows that more NMP (compared to ethanol)
remains in the ﬁlm upon UV curing.
Inclusion of the drug amorolﬁne HCl or terbinaﬁne HCl had no
inﬂuence on ﬁlm thickness (p > 0.05) or on its microstructure. The
amount of drug included in the formulation was below the
saturation limit, i.e. the drugs were molecularly dispersed in the
formulation, and was fairly low. It seems that such a low drug load
caused no visible changes in the ﬁlm’s microstructure.bition layer. Means  standard deviation are shown, n = 3. NA = not applicable.
 amorolﬁne HCl Film containing terbinaﬁne HCl
Drug yield Mass yield Drug yield
NA NA NA
87.1  1.3 86.5  1.7 87.1  0.9
87.2  2.2 85.5  1.5 87.1  2.7
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Fig. 6. FT-IR spectra of ﬁlms produced from the UV-curable gels (solvent and drug). The absorption bands circled relate to the C¼O stretch of NMP’s ﬁve ring lactam.
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As previously mentioned, ethanol-containing gels (prior to
curing) could incorporate a maximum of 3% w/v amorolﬁne HCl
or 4% w/v terbinaﬁne HCl, while NMP-containing gels could
contain 1% w/v of either amorolﬁne HCl or terbinaﬁne HCl in the
dissolved form. Upon UV-curing, the drug remained in the
dissolved state and no crystals were observed by polarised light
microscopy. The absence of drug crystals in the UV-cured ﬁlm was
conﬁrmed by DSC (which showed an absence of endothermic
peaks related to the drugs’ melting point), polarised lightFig. 7. TGA proﬁles of UV-cured polymer ﬁlmsmicroscopy and by XRD which also showed the ﬁlms (both
drug-loaded and control) to be amorphous (Figs. 4–5 for
amorolﬁne). The DSC and XRD curves and polarised light
micrograph for terbinaﬁne-loaded ﬁlms were comparable to
those in Figs. 4–5, and are not shown.
The UV-cured polymer ﬁlms were expected to contain a
lower drug load compared to the uncured gel, due to the
removal of the oxygen-inhibition layer following curing. This
was indeed the case. Amorolﬁne was present at 2.6% (vs 3%
prior to curing) and at 0.9% (vs 1% prior to curing) in ﬁlms
produced from gels containing ethanol and NMP respectively, produced from gels (solvent and drug).
Table 6
Tg values of UV-cured polymer ﬁlms.
Formulation Tg (C)
Solvent-free and drug-free gel 85.7  1.2 and 146.0  2.5
Drug-free gel containing ethanol 112.5  1.8
Gel containing ethanol and 3% w/v Amorolﬁne HCl 109.2  1.1
Gel containing ethanol and 4% w/v Terbinaﬁne HCl 109.6  0.8
Drug-free gel containing NMP 95.1  1.5
Gel containing NMP and 1% w/v Amorolﬁne HCl 94.8  2.0
Gel containing NMP and 1% w/v Terbinaﬁne HCl 95.0  1.8
186 L.V. Kerai et al. / International Journal of Pharmaceutics 492 (2015) 177–190while terbinaﬁne was present at 3.5% (vs 4% prior to curing) and
0.9 % (vs 1% prior to curing) in the corresponding ﬁlms. The
percentage drug loss reﬂects the percentage polymer ﬁlm loss
upon removal of the oxygen inhibition layer (Table 5). The fact
that the ﬁlm and drug losses are almost the same indicates that
there was no drug migration to the ﬁlm surface or interior
during UV curing.
The FT-IR spectra of the drug-free and drug-loaded polymer
ﬁlms showed no shifts in the characteristic bands (Fig. 6),
indicating the absence of drug-polymer interactions in the ﬁlm.
This bodes well for drug release from ﬁlm and ungual drug
permeation.
Interestingly, the FT-IR spectra of the ﬁlms produced from the
NMP containing formulations show an absorption band between
1670 and 1710 cm1 relating to the C¼O stretch of NMP’s ﬁve ring
lactam, suggesting that NMP becomes incorporated into the
polymer upon curing. Presence of NMP in the ﬁlm could be due to
its high boiling point (204.3 C) such that the solvent does not
evaporate off upon curing.0
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Fig. 9. Water sensitivity score of UV-cured ﬁlms (solvent a3.7. Thermal properties of ﬁlms
The thermal properties of the ﬁlms were determined using TGA
and DMA and the inﬂuence (if any) of solvent and drug
incorporation on the ﬁlm’s glass transition temperature and
degradation were evaluated.
The TGA curves for the polymer ﬁlms (with and without solvent
and drug) are shown in Fig. 7. The proﬁles seem to consist of four
phases, a–d, and are similar to those reported by Kunwong et al.
(2011) for UV-cured coatings based on urethane acrylate oligomers.
The ﬁrst phase relates to the loss of volatile materials from the ﬁlm as
the latter is heated. Films produced from solvent-containing
formulations showed a greater loss in mass than the control drug-
free, solvent-free ﬁlm during phase a (p < 0.05). This indicates that
some of the solvent which remained in the ﬁlm upon UV-curing was
being lost as the ﬁlm was heated. NMP-containing ﬁlms showed a
greater mass loss than ethanol-containing ones and a transition at
around 200 C. This is linked to the greater amount of residual
solvent in these ﬁlms (as discussed in Section 3.5) and to NMP’s
boiling point of 204 C. Phases b–d in the proﬁles are related to
polymerdecomposition via the degradation of polymer side-chains,
followed byscission and depolymerisation, and ﬁnallycomplete de-
crosslinking and thermal degradation, as suggested for similar ﬁlms
by other researchers (Chattopadhyay and Webster, 2009).
Dynamic Mechanical Analysis (DMA) Tg values are shown in
Table 6. The DMA curves for the solvent-free ﬁlms showed two
transitions at 86 C and at 146 C. This indicates two types of
polymer chains/ areas in the ﬁlm, with one containing more cross-
links (and hence showing a higher Tg) than the other. The greater
cross-linking would have occurred when both methacrylate
groups on the diurethane dimethacrylate monomer would have%
inaﬁne
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gel resulted in ﬁlms with one Tg only – which was around the mid-
point of the two values seen in the solvent-free ﬁlms. It was
mentioned earlier that inclusion of a solvent considerably
decreased the viscosity of the gel. This could have resulted in
greater mobility of the reactants and consequently a more
homogenous polymerisation process and thereby a more homog-
enous type of cross-linked polymer ﬁlm with one Tg. Interestingly,
ﬁlms formed from NMP-containing gels have lower (paired t-test,
p < 0.05) Tg values than ethanol-containing ones. The greater
amount of residual solvent in the NMP-based ﬁlm (as discussed in
Section 3.5 and evidenced in Fig. 7) seems to result in a plasticising
effect on the UV-cured polymer ﬁlm, such that Tg is lowered. In
contrast, the presence of the drugs in the ﬁlms does not cause any
signiﬁcant changes in the ﬁlm Tg, possibly due to their low
concentrations.
3.8. Film adhesion to substrate
The mean cross-cut score of the polymer ﬁlms is shown in Fig. 8.
A high score means lower adhesion (or resistance to separation
from a substrate). The greatest adhesion was shown by the ﬁlms
produced from the drug-free, solvent-free formulation. Presence of
ethanol (with and without antifungal drugs) in the formulation
caused no statistically signiﬁcant change in ﬁlm adhesion
(p > 0.05). In contrast, presence of NMP (with and without
antifungal drugs) signiﬁcantly reduced the adhesivity (p < 0.05).
As discussed earlier, more NMP (than ethanol) remains in the ﬁlm
upon gel curing. The presence of a greater amount of solvent causes
a larger change in the properties of the NMP-containing ﬁlms
resulting in a signiﬁcant decrease in ﬁlm adhesion to the substrate.
The incorporation of either amorolﬁne HCl or terbinaﬁne HCl in the
formulation did not affect the ﬁlms cross-cut score (p > 0.05);
possibly due to the small percentage of drug in the ﬁlm.Fig. 10. Stability of stored: (1) Gel formulation – drug concentration and the quality of th
over time and (2) Polymer ﬁlm – drug crystallisation and drug concentration over tim3.9. Film sensitivity to water
The water sensitivity of the UV-cured ﬁlms are shown in Fig. 9. It
can be seen that ﬁlms producedby the NMP-containingformulations
are extremely water sensitive; by 5 h the ﬁlms had detached from the
substrate. NMP is miscible in water (Jouyban et al., 2010) and as it is
present at a considerable level in the ﬁlm, contact with water
increases the latter’s water sensitivity. In contrast, solvent-free and
drug-free ﬁlms had the lowest watersensitivity. Thiswasexpectedas
urethane methacrylate based ﬁlms are known for water resistance.
Inclusion of ethanol caused no signiﬁcant change (p < 0.05) in water
sensitivity. Like NMP, ethanol is miscible in water and therefore one
could have expected the water sensitivity of ethanol-and
NMP-containing ﬁlms to be comparable. A possible explanation
for the greater water sensitivity displayed by NMP containing ﬁlms
is that the large planar nonpolar region of NMP intercalates among
polymer chains forming hydrophobic interactions with the
polymer, whereas most of the ethanol evaporates off during and
after curing due to its lower boiling point. The incorporation of
either amorolﬁne HCl or terbinaﬁne HCl in the formulation did not
affect the ﬁlms’ water sensitivity, possibly due to the very low drug-
load. A low water sensitivity of ﬁlms produced from ethanol and
drug containing gels indicates that these could be used as long-term
topical nail medicines, water sensitivity of ﬁlms being a good
predictor of their in vivo residence (Murdan et al., 2015). The high
water sensitivity of NMP-containing ﬁlms means that these ﬁlms
would not remain on the nail in vivo for prolonged periods. These
ﬁlms were therefore not included in the work described in the
following sections.
3.10. Stability
Both the gel formulations and the UV-cured ﬁlms were stored
under accelerated stability conditions and assessed for any changese ﬁlm produced (in terms of drug concentration and the presence of drug crystals)
e. Mean  standard deviation are shown for drug concentrations, n = 3.
Fig. 11. Cumulative% drug release from the UV-cured ﬁlms and Curanail. Means  standard deviation are shown, n = 3. Polarised light microscopy images (pre- and post-
release) are shown alongside their corresponding release proﬁles.
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the gel formulations were also tested at time intervals during
storage for the quality of the ﬁlms produced upon UV-curing, in
terms of drug state (amorphous/crystalline) and load. Over a
period of three months the drug-loaded gel formulations showed
no changes in colour (not shown), consistently produced polymer
ﬁlms that were free of drug crystals and showed no signiﬁcant
changes (p > 0.05) in drug concentration in the gel as well as in the
polymer ﬁlms produced (Fig. 10). The UV-curable gel formulations
are therefore stable for three months. In contrast, stored polymer
ﬁlms show a change in the state of the drug, drug crystals being
visible from week 3 (Fig. 10). Drug precipitation in the ﬁlms could
be due to the loss of residual ethanol solvent from the polymer ﬁlm
over time.
3.11. Drug release
The drug release proﬁles from the UV-cured polymer ﬁlms are
shown in Fig. 11, along with that of Curanail. The latter is a0
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Fig. 12. Cumulative amount of drug permeated across the nail from the UVcommercially available nail lacquer containing amorolﬁne HCl at
5% w/v. Upon evaporation of the solvent, a polymer ﬁlm containing
drug at 31.5  0.8% w/w is formed (measured by dissolving the
Curanail ﬁlm in ethanol and quantifying by HPLC). This ﬁlm was
used as a comparison in these release studies.
A burst of drug release from all three ﬁlms was found in the ﬁrst
24 h, due to release of drug found at the surface of the ﬁlms.
Subsequently, drug release slowed and plateaued by day 10.
Curanail ﬁlm showed almost complete drug release, possibly due
to its high water-sensitivity (Murdan et al., 2015) such that the ﬁlm
largely dissolved during the experiment and released the drug. In
contrast, UV-cured ﬁlms only released part of the incorporated
drug, with terbinaﬁne release being signiﬁcantly less than that of
amorolﬁne (p < 0.05). The relatively low drug release from
UV-cured ﬁlms indicates a high afﬁnity of the drugs for the
UV-cured ﬁlms. It is also possible that the UV-cured ﬁlms are
highly cross-linked, and that the pore sizes are such that diffusion
of the drug molecules through the ﬁlm is limited. It is unclear why
terbinaﬁne release is almost half that of amorolﬁne; the two drugs 18 21 24 27 30
e (days)
-cured and Curanail ﬁlms. Mean  standard deviation are shown, n = 6.
Table 7
Lag time, steady-state ﬂux, permeability coefﬁcient, diffusion coefﬁcient and amount of drug in nail clippings. Means  standard deviation are shown, n = 6. Statistical
differences were determined using the t-test.
Formulation Lag time
(day)
Steady-state ﬂux
(mg/cm2/day)
Permeability
coefﬁcientx105 (cm/day)
Diffusion
coefﬁcient  105 (cm2/
day)
Drug in nail clipping
(mg/cm2)
Curanail ﬁlm (32% wt. Amorolﬁne HCl) 10.4  1.3 2.9  0.2 5.8  0.3 2.5  0.5 61.1  14.8
3% wt. Amorolﬁne HCl UV-cured ﬁlm 10.4  0.9 2.4  0.2 7.9  0.7 2.7  0.8 37.5  17.6
4% wt. Terbinaﬁne HCl UV-cured ﬁlm 9.5  1.2 1.5  0.1 3.7  0.3 1.6  0.4 71.1  8.0
Statistical difference between Curanail and
amorolﬁne UV-cured ﬁlm?
No
(p > 0.05)
Yes (p < 0.05) Yes (p < 0.05) No (p > 0.05) Yes (p < 0.05)
Statistical difference between amorolﬁne and
terbinaﬁne UV-cured ﬁlm?
No
(p > 0.05)
Yes (p < 0.05) Yes (p < 0.05) Yes (p < 0.05) Yes (p < 0.05)
Table 8
Mass balance in permeation experiment at day 30. Means  standard deviations are shown, n = 6.
Formulation Percentage drug recovered
Receptor (i.e. permeated) Nail clipping Donor (i.e. ﬁlm remaining on the nail plate surface) Total
Curanail ﬁlm 1.0  0.1 1.6  0.4 96.9  1.4 99.5  1.3
UV-cured ﬁlm with amorolﬁne 1.7  0.2 1.8  0.9 96.4  1.4 99.9  1.4
UV-cured ﬁlm with terbinaﬁne 0.8  0.1 2.6  0.3 96.4  1.1 99.8  1.1
L.V. Kerai et al. / International Journal of Pharmaceutics 492 (2015) 177–190 189have similar logP values (5.8 and 5.3 for amorolﬁne HCl and
terbinaﬁne HCl respectively) and molecular weights (353.97 and
327.89 Da for amorolﬁne HCl and terbinaﬁne HCl respectively), and
sink conditions were maintained for both drugs during the study. A
low drug release could occur if terbinaﬁne was incorporated in the
polymer structure upon UV-curing. Terbinaﬁne does have the
potential to take part in the polymerisation process due to its
alkene group. However we do not think this occurred as most of
the drug included in the gel mixture could be extracted from the
UV-cured ﬁlm (just as amorolﬁne HCl could be). Polarised light
micrographs of the UV-cured ﬁlms (pre- and post-release study)
are similar for the two drugs and show no obvious change during
the release study and do not offer any clues to the lower terbinaﬁne
release. In contrast to the UV-cured ﬁlms, the Curanail ﬁlm
contained a much greater drug-load at 32% w/w. Such a high drug-
load caused amorolﬁne HCl precipitation into crystals (shown in
the pre-release polarised light micrograph in Fig. 11).
3.12. Ungual drug permeation
The ungual drug permeation proﬁles from the polymer ﬁlms are
shown in Fig. 12, while the calculated lag times, study-state ﬂux,
apparent permeability coefﬁcients, effective diffusion coefﬁcients
and amount of drug in nail clippings are shown in Table 7 and the
mass balance calculations in Table 8.
The ungual permeation proﬁles are signiﬁcantly different from
one another (p < 0.05), but the rank order of the formulations is the
same as the release proﬁles, i.e. Curanail > amorolﬁne HCl-loaded
UV-cured ﬁlm > terbinaﬁne HCl-loaded UV-cured ﬁlm. This indi-
cates that drug release from the ﬁlms may be a rate-limiting step to
ungual drug permeation. At the same time, similar lag times
(approximately 10 days) for all three ﬁlms show the critical role
played by the nail plate barrier to ungual drug permeation.
From Table 7, it can be seen that terbinaﬁne HCl-containing
UV-cured ﬁlms showed a lower drug ﬂux compared to amorolﬁne
HCl-containing ones (p < 0.05), but achieved greater drug con-
centrations in the nail (p < 0.05). The lower drug ﬂux could be due
to a lower terbinaﬁne release by the ﬁlm (shown in Fig. 11) and/or
due to greater terbinaﬁne-nail keratin afﬁnity which could have
resulted in the greater terbinaﬁne concentration in the nail.
Terbinaﬁne has previously been shown to bind more strongly tokeratin compared to amorolﬁne (Tatsumi et al., 2002). While drug
binding to keratin has been correlated to a reduction in a drug’s
antifungal potency (Tatsumi et al., 2002), it could also result in the
creation of a drug reservoir in the nail, which could be beneﬁcial
over the longer term. The nail keratin would then act as a drug
depot releasing drug over time to (i) kill the fungus and any newly-
germinating fungal spore residing in the nail plate and (ii)
permeate into the nail bed to exert anti-fungal action there.
The comparator – Curanail – achieved higher drug ﬂux as well
as higher drug concentration in the nail clipping compared to the
amorolﬁne-loaded UV-cured ﬁlm (p < 0.05, Table 7). This could be
due to its higher drug-load (32% w/w vs 3% w/w), hence a greater
drug concentration gradient between the donor and the receptor
phases, and a greater amount of drug released (seen in Fig. 11).
Whether this difference in drug ﬂux and drug concentration in nail
translates to greater anti-onychomycotic efﬁcacy remains to be
seen in vitro and in vivo. Compared to Curanail’s in vivo residence
of a few days (Murdan et al., 2015), the UV gel is expected to have a
much longer residence on the nail in vivo, like its cosmetic
counterparts. The long residence would mean less frequent drug
application, which could result in greater patient compliance and
thereby higher success of therapy.
Table 8 shows that for both Curanail and the UV-cured ﬁlms,
most of the drug remains in the ﬁlm and a very small proportion
enters the nail plate and the receptor medium. This very low
ungual permeation reﬂects previous reports in vitro and in man.
For example, vanHoogdalem et al. (1997) showed that less than
0.2% of the applied dose permeated ﬁngernails after 6 weeks in a
human volunteer study. However, despite the low percentage of
applied drug which permeates into the nail, the drug levels
achieved in the nailplate (shown in Table 7) are considerable when
the drugs’ minimum inhibitory concentrations (MICs) are taken
into account. The MICs of amorolﬁne and terbinaﬁne have been
reported to be 0.12–0.5 mg/ml and 0.004–0.06 mg/ml respectively
against Trichophyton rubrum, the most common cause of onycho-
mycosis (Tamura et al., 2014). Although these MIC values
determined in vitro in broth, are not expected to be directly
applicable to MICs in the nailplate, they do indicate that the drug
levels achieved in the nail are more than sufﬁcient to cause fungal
kill. Thus, we can conclude that the UV-cured ﬁlms are promising
candidates for the topical treatment of onychomycosis.
190 L.V. Kerai et al. / International Journal of Pharmaceutics 492 (2015) 177–1904. Conclusions
UV-curable gels show promise as topical ungual drug carriers.
Anti-onychomycotic drugs can be incorporated within these gels,
in the presence of a suitable solvent. Ethanol-containing for-
mulations have favourable properties such as high stability and
water resistance. The drug is slowly released from the ﬁlm and
permeates into and through the nailplate. This is the ﬁrst report of
the potential of UV-curable gels – commonly used as cosmetics – as
topical ungual drug carriers. Such formulations are used as
cosmetics for their long residence on the nail. It is expected that
the drug-loaded formulations will also have a long residence on
the nail, allowing drug permeation into the nail over a long time.
This is expected to improve topical therapy of nail diseases.
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